SynthesisFrontiers in public health2025
Clinical efficacy and safety of proton radiotherapy for ocular conjunctival malignancies: a systematic review and meta-analysis.
Synthesis in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The use of proton beam therapy (PBT) for treating ocular conjunctival malignancies is on the rise across numerous medical centers. This study conducts a systematic review and meta-analysis to assess the effectiveness and safety of PBT in treating malignant conjunctival tumors. Methods: We searched for studies on PBT for ocular conjunctival malignancies in PubMed, Embase, Cochrane Library, and Web of Science (WoS) databases up to November 25, 2023. Studies were selected and data were extracted by two independent reviewers based on pre-established inclusion and exclusion criteria. The quality of evidence was assessed using the GRADE method. Meta-analysis was performed using STATA version 16.0. Results: An initial search yielded 586 articles, from which six retrospective case series studies were selected involving 291 patients with ocular conjunctival malignancies, including 240 cases of conjunctival melanoma and 51 cases of conjunctival squamous cell carcinoma (SCC). Meta-analysis with a random-effects model showed that PBT is effective and relatively safe, with 2-, 4-, and 5-year overall survival (OS) rates of 98% (95% CI 95-102%), 87% (95% CI 69-104%), and 78% (95% CI 70-87%) respectively. Reported toxicity rates included 19% for cataracts, 10% for glaucoma, 5% for lacrimal stenosis, 52% for sicca symptoms, and 11% for limbal stem cell deficiency. The GRADE assessment yielded a low certainty of evidence. Conclusions: Proton therapy offers a viable alternative treatment for patients with conjunctival malignancies, with acceptable treatment-related toxicity rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.